Q/C TECHNOLOGIES, INC.
Q/C TECHNOLOGIES, INC. (QCLS): 5 pipeline candidates · 1 upcoming catalyst · ~12 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
11.5 months
D/E 0.70 · 3% dilution
Lead: Approved
5 candidates
1 upcoming, next in ~195d
1 buy · 0 sells (180d)
A transparent, data-derived signal for Q/C TECHNOLOGIES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$30.4M
Cash
$1.1M
Quarterly Burn
$3.3M
Runway
11.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| buprenorphine | Approved |
| clonidine | Approved |
| isomyosamine | Phase 2 |
| leniolisib | Phase 3 |
| supera-cbd | Preclinical |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$1.9M
| Holder | Shares | Value |
|---|---|---|
| quinn opportunity partners llc | 211,390 | $729K |
| jane street group, llc | 126,188 | $435K |
| vanguard capital management llc | 75,022 | $259K |
| adar1 capital management, llc | 50,000 | $173K |
| geode capital management, llc | 47,390 | $163K |
| dimensional fund advisors lp | 19,058 | $66K |
| vanguard fiduciary trust co | 15,555 | $54K |
| state street corp | 12,905 | $45K |
| sunbelt securities, inc. | 1,750 | $6K |
| tower research capital llc (trc) | 1,593 | $5K |
Showing top 10 of 17 institutional holders of Q/C TECHNOLOGIES, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Q/C TECHNOLOGIES, INC.'s pipeline?
Q/C TECHNOLOGIES, INC. (QCLS) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Q/C TECHNOLOGIES, INC.'s lead drug candidate?
Q/C TECHNOLOGIES, INC.'s most advanced tracked candidate is buprenorphine (Approved).
What is Q/C TECHNOLOGIES, INC.'s next catalyst?
Q/C TECHNOLOGIES, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of L" — expected December 30, 2026.
What is Q/C TECHNOLOGIES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Q/C TECHNOLOGIES, INC. has approximately 11.5 months of cash runway.
What is Q/C TECHNOLOGIES, INC.'s market capitalization?
Q/C TECHNOLOGIES, INC.'s market capitalization is approximately $30.4M.
Get the full picture on Q/C TECHNOLOGIES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.